Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. US FDA. Biological Product Definitions. FDA. https://www.fda.gov/media/108557/download. Accessed 25 Oct 2019.
2. The Vision Academy Steering Committee, Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–73.
3. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019; pii: S0161-6420(18)33018-5.
4. Sharma A, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Brolucizumab: is extended VEGF suppression on the horizon? Eye (Lond). 2019. https://doi.org/10.1038/s41433-019-0582-0.
5. Sharma A, Kumar N, Kuppermann BD, Bandello F. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (Lond). 2019. https://doi.org/10.1038/s41433-019-0607-8.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献